FDA extends review period for Ascendis Pharma's first drug
![Photo: Kevin Grønnemann](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11298514.ece/ALTERNATES/schema-16_9/ascendis.jpg)
Just two weeks before the deadline, the US Food and Drug Administration (FDA) has extended the review period for Ascendis Pharma's first drug candidate lonapegsomatropin, according to an Ascendis Pharma press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Ascendis increases expenses shortly before moment of truth
For subscribers